Will Vimpat help UCB survive generic Keppra?
The start of September has been positive for UCB, with the EC approving Vimpat (lacosamide) as adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in patients with epilepsy aged 16 years and older (for further details, see Anti-Epileptics, Product News). UCB has extensive experience in the epilepsy field, having marketed Keppra (levetiracetam), which is indicated for the treatment of several types of epilepsy, including add-on treatment for adults and children from four years of age with partial onset seizures, since 2000. However, the company is now facing the introduction of generic versions of Keppra. Under the terms of a settlement agreement with UCB and subject to its receiving FDA approval, Mylan will be allowed to sell its generic levetiracetam tablets effective 1st November, in advance of the expiry of UCB’s market exclusivity on 14th January 2009. UCB has been working to delay the introduction of generic Keppra and minimise th
Related Questions
- Can you recommend anything else that might survive on the bubble tip side of the fence so to speak that will help cover the rocks and provide a nice backdrop apart from the algae on the rocks?
- How are mariners and researchers trying to help right whales survive?
- Will Vimpat help UCB survive generic Keppra?
